GE aiming to be cell therapy production services one-stop-shop

By Dan Stanton

- Last updated on GMT

Image: iStock/dumfstar
Image: iStock/dumfstar

Related tags Ge healthcare Cell therapy Stem cell

GE Healthcare has acquired cryopreservation technology firm Asymptote and says more investments are likely as it builds an “end-to-end ecosystem” for cellular therapy production services.

Financial details of the deal have not been divulged, but GE Healthcare will add 13 employees through the acquisition of Cambridge, UK-based Asymptote, an emerging player in the cold chain space which has seen double digit growth over the past few years.

“Asymptote has a suite of technologies for the cryopreservation of cellular materials that supports safe manufacture and delivery of cell therapies,”​ Ger Brophy, GM of GE Healthcare’s Cell Therapy business told Biopharma-Reporter.

“Their offering fills a critical gap in GE Healthcare’s end-to-end ecosystem of products and services for cell therapy production.”

GE adds a number of technologies through the acquisition, including an application of the Stirling cryocooler which removes heat by conduction from containers allowing accurate and consistent cooling rates in samples, he said, and a soon-to-be released VIA Thaw platform which gently warms up deeply frozen cells by a water-free conduction process.

“All Asymptote thawers work without using water or any other fluid, they are all fully-automated and tightly control the thawing process. Every unit synchronizes thawing programs and data logs from each thaw to a centralized platform accessible from a web browser or mobile device.”

GE and cell therapies

Incorporating the cryopreservation technologies into GE’s portfolio will prep the firm for the expected increase in demand for manufacturing and clinical delivery as the cell therapy sector develops, Brophy told us.

“Already we have been aware of the need for cold-chain management in the industry, spanning all elements of regenerative medicine from cell bank creation, to patient sample management. The digital enablement of these devices adds the benefit of improved temperature logging for critical cell samples.”

Last year​ the firm acquired the Biosafe Group, incorporating its single-use cell processing and separation tech into its cellular therapy offerings, and according to Brophy more acquisitions may be on the cards.

“GE is building an end-to-end ecosystem of products and services for cell therapy production, the same way we are serving the biopharmaceutical companies and their production processes today. We don’t comment on potential acquisitions but we view cell therapy as a field where we want to continue to make investments.”

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more